Biomarkers of atherosclerosis: Clinical applications

被引：30

作者：

Brown T.M. ^{[1
]}

Bittner V. ^{[1
]}

机构：

[1] Department of Preventive Cardiology, University of Alabama at Birmingham, Division of Cardiovascular Disease, Birmingham, AL 35294-0007

来源：

Current Cardiology Reports | 2008年 / 10卷 / 6期

基金：

美国医疗保健研究与质量局;

关键词：

Coronary Artery Calcium; Brain Natriuretic Peptide; Rosuvastatin; Coronary Artery Calcium Score; Traditional Risk Factor;

D O I：

10.1007/s11886-008-0078-1

中图分类号：

学科分类号：

摘要：

Current cardiovascular risk prediction models incorporate traditional risk factors to estimate 10-year cardiovascular risk. Numerous blood-based biomarkers have been identified that are associated with increased cardiovascular risk after adjusting for traditional risk factors. Many of these biomarkers, alone or in combination, have been incorporated into risk prediction models to determine whether their addition increases the model's predictive ability. We review the recently published literature on blood-based biomarkers and examine whether incorporating these markers may improve clinical decision making. © Current Medicine Group LLC 2008.

引用

页码：497 / 504

页数：7

共 50 条

[11]

van der Steeg W.A., Boekholdt S.M., Stein E.A., Et al., Role of the apolipoprotein B-apolipoprotein A-1 ratio in cardiovascular risk assessment: A case-control analysis in EPIC-Norfolk, Ann Intern Med, 146, pp. 640-648, (2007)

[12]

Virani S.S., Polsani V.R., Nambi V., Novel markers of inflammation in atherosclerosis, Curr Atheroscler Rep, 10, pp. 164-170, (2008)

[13]

Nambi V., The use of myeloperoxidase as a risk marker for atherosclerosis, Curr Atheroscler Rep, 7, pp. 127-131, (2005)

[14]

Meuwese M.C., Stroes E.S., Hazen S.L., Et al., Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: The EPIC-Norfolk Prospective Population study, J Am Coll Cardiol, 50, pp. 159-165, (2007)

[15]

Garza C.A., Montori V.M., McConnell J.P., Et al., Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: A systematic review, Mayo Clin Proc, 82, pp. 159-165, (2007)

[16]

Ballantyne C.M., Hoogeveen R.C., Bang H., Et al., Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study, Arch Intern Med, 165, pp. 2479-2484, (2005)

[17]

Ridker P.M., C-reactive protein and the prediction of cardiovascular events among those at intermediate risk, J Am Coll Cardiol, 49, pp. 2129-2138, (2007)

[18]

Sabatine M.S., Morrow D.A., Jablonski K.A., Et al., Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease, Circulation, 115, pp. 1528-1536, (2007)

[19]

Pearson T.A., Mensah G.A., Alexander R.W., Et al., Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association, Circulation, 107, pp. 499-511, (2003)

[20]

Vidula H., Tian L., Liu K., Et al., Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: A cohort study, Ann Intern Med, 148, pp. 85-93, (2008)

← 1 2 3 4 5 →